Age Related Macular DegenerationNCT06943599
Strategies for Improving Linkage-to-Care After Eye Disease Screening
A study testing Text Message Reminder and Health Worker Visit in people with Age Related Macular Degeneration and Diabetic Retinopathy, run by University of California, San Francisco at 1 site in United States.
Trial summary
The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
- What is being tested?
- Text Message Reminder and Health Worker Visit
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,000 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2026to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant of the VIEW II study referred to the eye hospital at their eye screening visit.
Who cannot join
- Residence in an area without reliable mobile connectivity
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Krisianne Aromin contact
United States1 site, 1 recruiting
- Recruiting
University of California, San Francisco
San Francisco, California, 94158
About this study
Official title: Village Integrated Eye Worker II Linkage-to-Care Trial
The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.
- Being tested
- Text Message Reminder, Health Worker Visit
- Keywords
- Eye Diseases, mass screening, patient compliance, retention in care
- Medical subject headings
- Macular Degeneration, Diabetic Retinopathy, Glaucoma, Eye Diseases, Patient Compliance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Text Message ReminderOther
Participants referred to the eye hospital after screening will receive a text message reminding them to attend their referral visit.
Health Worker VisitOther
Participants referred to the eye hospital after screening will receive a home visit from a health worker reminding them to attend their referral visit.
| Study group | Role | What they receive |
|---|---|---|
| Text Message Reminders | Experimental | Not described Receives: Other: Text Message Reminder |
| Health Worker | Experimental | Not described Receives: Other: Health Worker Visit |
| No Intervention | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Referral Visit Attendance
The count of participants who attend the referral visit.
Measured: 21 days after screening
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2025
- Study start1 Feb 2026
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age Related Macular DegenerationStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- Seva Foundation, National Eye Institute (NEI)
- Responsible party
- Sponsor
- Investigators
- Jeremy Keenan, MD, MPH, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06943599
- Sponsor's protocol ID
- 17-22776-3
- Other IDs
- UG1EY036346
- Status last verified
- Apr 2026
- First submitted
- 11 Apr 2025
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data including age, cluster identifier, referral visit attendance
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Village Integrated Eye Worker II Linkage-to-Care Trial
- ClinicalTrials.gov ID
- NCT06943599
- Acronym / sponsor ID
- 17-22776-3
- Keywords
- Eye Diseases, mass screening, patient compliance, retention in care
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Collaborators
- Seva Foundation, National Eye Institute (NEI)
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 24 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Text Message Reminders | Experimental | Other: Text Message Reminder |
| Health Worker | Experimental | Other: Health Worker Visit |
| No Intervention | No intervention | – |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Participant of the VIEW II study referred to the eye hospital at their eye screening visit.
Key exclusion criteria (1 listed)
- Residence in an area without reliable mobile connectivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Text Message ReminderParticipants referred to the eye hospital after screening will receive a text message reminding them to attend their referral visit. | Other | Text Message Reminders |
| Health Worker VisitParticipants referred to the eye hospital after screening will receive a home visit from a health worker reminding them to attend their referral visit. | Other | Health Worker |
Primary outcome
Referral Visit Attendance
Time frame: 21 days after screening
The count of participants who attend the referral visit.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: Yes. De-identified data including age, cluster identifier, referral visit attendance
Related trials for Age Related Macular Degeneration
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
RecruitingObservational study
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingObservational study
Retinal Pigment Epithelium Safety Study For Patients In B4711001
Age Related Macular Degeneration
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Krisianne Aromin contact
Jeremy Keenan, MD, MPH principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Text Message Reminder and Health Worker Visit in people with Age Related Macular Degeneration and Diabetic Retinopathy, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jeremy Keenan, MD, MPH ((415) 476-1442, jeremy.keenan@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Referral Visit Attendance (time frame: 21 days after screening). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.